IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v38y2020i7d10.1007_s40273-020-00902-w.html
   My bibliography  Save this article

Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden

Author

Listed:
  • Julia Widén

    (Quantify Research AB)

  • Magnus Ivarsson

    (Vifor Pharma Nordiska AB)

  • Lovisa Schalin

    (Vifor Pharma Nordiska AB)

  • Polina Vrouchou

    (Vifor Pharma Ltd)

  • Matthias Schwenkglenks

    (Institute of Pharmaceutical Medicine (ECPM), University of Basel)

  • Olof Heimbürger

    (Karolinska University Hospital
    CLINTEC, Karolinska Institutet)

  • Zanfina Ademi

    (Institute of Pharmaceutical Medicine (ECPM), University of Basel
    Monash University)

  • C. Simone Sutherland

    (Institute of Pharmaceutical Medicine (ECPM), University of Basel)

Abstract

Objectives Patients with chronic kidney disease (CKD) are commonly treated with renin–angiotensin–aldosterone system inhibitors (RAASi) in order to delay progression of renal disease. However, research has shown that RAASi in CKD patients increases hyperkalaemia (HK) prevalence, which leads to RAASi discontinuation or dose reduction with the loss of benefits on the kidney. Patiromer is a novel therapy for HK treatment and may enable patients to remain on their RAASi regimen. This study aimed to assess the cost-effectiveness of patiromer from a Swedish healthcare perspective. Methods A Markov model was developed to evaluate the economic outcomes of patiromer versus no patiromer in HK patients with stage 3–4 CKD taking RAASi. The model consisted of six health states reflecting disease progression and hospitalisations. The analysis mainly considered clinical data from the OPAL-HK trial and national costs. The main outcomes of interest were incremental costs (euro [EUR] 2016) and quality-adjusted life years (QALYs), discounted at 3%, and the incremental cost-effectiveness ratio (ICER). Extensive uncertainty analyses were performed. Results In comparison to no patiromer, a patiromer patient gained 0.14 QALYs and an incremental cost of EUR 6109 (Swedish krona [SEK] 57,850), yielding an ICER of EUR 43,307 (SEK 410,072)/QALY gained. The results were robust to a range of sensitivity analyses. At a willingness-to-pay threshold of EUR 52,804 (SEK 500,000)/QALY, patiromer had a 50% chance of being cost-effective. Conclusions The results indicate that patiromer may demonstrate value for money in Swedish patients with stage 3–4 CKD, by enabling RAASi treatment. However, there is a considerable degree of uncertainty.

Suggested Citation

  • Julia Widén & Magnus Ivarsson & Lovisa Schalin & Polina Vrouchou & Matthias Schwenkglenks & Olof Heimbürger & Zanfina Ademi & C. Simone Sutherland, 2020. "Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden," PharmacoEconomics, Springer, vol. 38(7), pages 747-764, July.
  • Handle: RePEc:spr:pharme:v:38:y:2020:i:7:d:10.1007_s40273-020-00902-w
    DOI: 10.1007/s40273-020-00902-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-020-00902-w
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-020-00902-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Melanie Wyld & Rachael Lisa Morton & Andrew Hayen & Kirsten Howard & Angela Claire Webster, 2012. "A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments," PLOS Medicine, Public Library of Science, vol. 9(9), pages 1-10, September.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Fabio Ferretti & Andrea Pozza & Maurilio Pallassini & Lorenzo Righi & Fulvia Marini & Sabrina Adami & Anna Coluccia, 2019. "Gender invariance of dignity in non-terminal elderly patients with chronic diseases: a multicentric study," Quality & Quantity: International Journal of Methodology, Springer, vol. 53(3), pages 1645-1656, May.
    2. Baris Ata & Yichuan Ding & Stefanos Zenios, 2021. "An Achievable-Region-Based Approach for Kidney Allocation Policy Design with Endogenous Patient Choice," Manufacturing & Service Operations Management, INFORMS, vol. 23(1), pages 36-54, 1-2.
    3. Wenjuan Fan & Yang Zong & Subodha Kumar, 2022. "Optimal treatment of chronic kidney disease with uncertainty in obtaining a transplantable kidney: an MDP based approach," Annals of Operations Research, Springer, vol. 316(1), pages 269-302, September.
    4. Redeker, Steef & Massey, Emma K. & van Merweland, Ruben G. & Weimar, Willem & Ismail, Sohal Y. & Busschbach, Jan J.V., 2022. "Induced demand in kidney replacement therapy," Health Policy, Elsevier, vol. 126(10), pages 1062-1068.
    5. Adedokun Oluwafemi Ojelabi & Afolabi Elijah Bamgboye & Jonathan Ling, 2019. "Preference-based measure of health-related quality of life and its determinants in sickle cell disease in Nigeria," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-16, November.
    6. Pedro García-Martínez & Rafael Ballester-Arnal & Kavita Gandhi-Morar & Jesús Castro-Calvo & Vicente Gea-Caballero & Raúl Juárez-Vela & Carlos Saus-Ortega & Raimunda Montejano-Lozoya & Eva María Sosa-P, 2021. "Perceived Stress in Relation to Quality of Life and Resilience in Patients with Advanced Chronic Kidney Disease Undergoing Hemodialysis," IJERPH, MDPI, vol. 18(2), pages 1-10, January.
    7. Trevor A. Ellison & Samantha Clark & Jonathan C. Hong & Kevin D. Frick & Dorry L. Segev, 2021. "Potential Unintended Consequences of National Infectious Disease Screening Strategies in Deceased Donor Kidney Transplantation: A Cost-Effectiveness Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 403-414, May.
    8. Fan Yang & Nancy Devlin & Nan Luo, 2019. "Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 99-105, February.
    9. Steef Redeker & Sohal Ismail & Hester V. Eeren & Emma K. Massey & Willem Weimar & Mark Oppe & Jan Busschbach, 2022. "A dynamic Markov model to assess the cost-effectiveness of the Kidney Team at Home intervention in The Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(4), pages 597-606, June.
    10. Fan Yang & Carlos K. H. Wong & Nan Luo & James Piercy & Rebecca Moon & James Jackson, 2019. "Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(8), pages 1195-1206, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:38:y:2020:i:7:d:10.1007_s40273-020-00902-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.